Personalized prescription of imatinib in recurrent granulosa cell tumor of the ovary: case report
- Elena V. Poddubskaya1,2,
- Madina P. Baranova1,3,
- Daria O. Allina4,
- Marina I. Sekacheva2,
- Lyudmila A. Makovskaia5,
- Dmitriy E. Kamashev2,
- Maria V. Suntsova6,
- Viktoria S. Barbara7,
- Irina N. Kochergina-Nikitskaya8 and
- Alexey A. Aleshin9
- 1Clinical Center Vitamed, Moscow, 121309, Russia;
- 2I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, 119991, Russia;
- 3FSBEI FPE Russian Medical Academy of Continuing Professional Education MOH, Moscow, 125993, Russia;
- 4Department of Pathology, Morozov Children's City Hospital, Moscow, 119049, Russia;
- 5Faculty of Fundamental Medicine, Lomonosov Moscow State University, Moscow, 119991, Russia;
- 6Shemyakin–Ovchinnikov Institute of Bioorganic Chemistry, Moscow, 117997, Russia;
- 7Oncological Dispensary of the Republic of Karelia, Petrozavodsk, 185002, Russia;
- 8The Institute of General Pathology and Pathophysiology, Moscow, 125315, Russia;
- 9Stanford University School of Medicine, Stanford, California 94305, USA
- Corresponding author: ireha_08{at}mail.ru
Abstract
Ovarian cancer is the fifth leading cause of cancer-related female mortality and the most lethal gynecological cancer. In this report, we present a rare case of recurrent granulosa cell tumor (GCT) of the ovary. We describe the case of a 26-yr-old woman with progressive GCT of the right ovary despite multiple lines of therapy who underwent salvage therapy selection based on a novel bioinformatical decision support tool (Oncobox). This analysis generated a list of potentially actionable compounds, which when used clinically lead to partial response and later long-term stabilization of the patient's disease.
Footnotes
-
[Supplemental material is available for this article.]
- Received August 3, 2018.
- Accepted January 10, 2019.
This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted reuse and redistribution provided that the original author and source are credited.
